Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
p53-Pulsed Dendritic Cell Vaccine in Adjuvant NSCLC
NCT00019929Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2000
- Modality
- Whole Cell Cancer Vaccines, Peptides, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of mutant p53 peptide pulsed dendritic cell vaccine in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Aug 2000; status: completed.
02
Drugs
mutant p53 peptide pulsed dendritic cell vaccine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00019929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00019929.